MedTrace Logo

Assessment of the Efficacy and Safety of (HCQ) as a Prophylaxis for COVID19 for Health Professionals

NCT04349228 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2020-08-28

No results posted yet for this study

Summary

Assessment of the Efficacy and Safety of Hydroxychloroquine (HCQ) Administered as a Prophylaxis for Health Professionals Exposed to COVID19 and Working in Medical Intensive Care Units, in Tunisia. Multicentric, Randomized Comparative Study

Conditions

  • COVID19
  • Sars-CoV2
  • Hydroxychloroquine
  • Prophylaxis
  • Healthcare Worker

Interventions

DRUG

Hydroxychloroquine (HCQ)

Hydroxychloroquine (HCQ) 200mg/day

DRUG

Placebo oral tablet

Placebo of Hydroxychloroquine (HCQ) without any active substance

Sponsors & Collaborators

  • Eshmoun Clinical Research Center

    collaborator NETWORK

  • Datametrix

    collaborator INDUSTRY

  • Abderrahmane Mami Hospital

    lead OTHER

Principal Investigators

  • Jalila Ben Khelil, Pr · Hopital Abderrahmane Mami

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-04-28
Primary Completion
2020-07-15
Completion
2020-07-15

Countries

  • Tunisia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04349228 on ClinicalTrials.gov